104945-70-2

Upstream product

• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 2592-95-2 benzotriazol-1-ol 
• 2177-63-1 (S)-2-amino-4-(benzyloxy)-4-oxobutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 84979-60-2 Boc-Asp(OBzl)-Val-Tyr-NHNH-Troc 
• 1036718-07-6 (3S)-N-(O-benzyl-N-Boc-L-aspartyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester 
• 84993-67-9 C₅₃H₆₅N₁₃O₁₄ 
• 84979-63-5 Z-Arg(NO₂)-Lys(Z)-Asp(OBzl)-Val-Tyr-NHNH₂ 
• 84979-61-3 Boc-Lys(Z)-Asp(OBzl)-Val-Tyr-NHNH-Troc 
• 84979-72-6 H₂N-Lys(Z)-Asp(OBzl)-Val-Tyr-NHNH-Troc 
• 84979-62-4 Z-Arg(NO₂)-Lys(Z)-Asp(OBzl)-Val-Tyr-NHNH-Troc 
• 104945-73-5 H-Asp(Bzl)-Met-Glu(Bzl)-Tyr(Bzl)-OMe trifluoroacetic salt 
• 104945-71-3 Boc-Asp(Bzl)-Met-Glu(Bzl)-Tyr(Bzl)-OMe 

Relevant academic research and scientific papers

Novel nano-materials, RGD-tetrapeptide-modified 17β-amino-11α- hydroxyandrost-1,4-diene-3-one: Synthesis, self-assembly based nano-images and in vivo anti-osteoporosis evaluation

To find novel nano-materials with anti-osteoporosis activity and without side effects three novel anti-osteoporosis active amphiphiles, 17β-(RGD-AA-amido)-11α-hydroxyandrost-1,4-diene-3-one (5a: AA = Ser, 5b: AA = Val, 5c: AA = Phe), were constructed by coupling the bone resorption inhibiting active RGD-peptides and anti-osteoporosis active 17β-amino- 11α-hydroxyandrost-1,4-diene-3-one. In the solid state 5a, 5b and 5c exist as dispersed globes of 300 nm-14 μm in diameter, dispersed eggs of 110 nm-19 μm in diameter and beads of 238 nm-22 μm in diameter, respectively. In ultrapure water 1.1 μM of 5a, 5b and 5c form nano-globes of 33-400 nm, 16-278 nm and 54-187 nm in diameter, respectively. At an oral dose of 110 nmol kg -15a-c effectively inhibited mice from developing osteoporosis. In contrast to estradiol, 5a-c did not induce mice to develop endometrial hyperplasia and thrombus.

(3S)-N-(l-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: Synthesis, bioassay, 3D QSAR, and ADME analysis

To increase antithrombotic activity, 3S-tetrahydroisoquinoline-3-carboxylic acid (1) was modified with natural amino acids to form 19 novel dipeptide analogs, 3S-tetrahydroisoquinoline-3-carboxyamino acids (5a-s), targeting the intestinal peptide transport system. In vitro assay of 5a-s indicated that their potencies for inhibiting adenosine diphosphate (ADP), arachidonic acid (AA), platelet-activating factor (PAF), and thrombin (TH)-induced platelet aggregations were higher than that of 1. Additionally, in vivo assay of 5a-s indicated that their potencies for inhibiting thrombogenesis in rats were also higher than that of 1. Among the candidates, 5h with Ser attachment showed the most impressive features for further development. According to molecular field analysis based Cerius2 QSAR module, two equations (r, 0.961 and 0.988) correlating the structures with both in vitro and in vivo activities of 5a-s were established. ADMET calculations predict higher intestinal absorption for compounds 5a-s. Further investigation with 5h as a lead compound is underway.

Synthesis of 6-amino acid substituted 4,6,7,12-tetrahydro-4-oxoindolo[2, 3-a]quinolizines

In the presence of Na2CO3 (1S, 3S)- and (1R, 3S)-1-(2,2-dimethoxyethyl)-2-(1,3-dioxobutyl)-3-(1,3-dioxobutyl)oxymethyl-1,2,3, 4-tetrahydrocarboline (1) were transformed into (1S, 3S)- and (1R, 3S)-1-(2,2-dimethoxyethyl)-2-(1,3-dioxob

Synthesis of a proposed antigenic hexapeptide from Escherichia coli K88 protein fimbriae.

The hexapeptide Boc-Asp-Asp-Tyr-Arg-Gln-Lys-OMe is assembled by stepwise synthesis in solution with an overall yield of 44%. N alpha-boc-amino acids, protected with benzyl or benzyloxycarbonyl groups in the side-chains, are coupled as active estes of 1-hydroxybenzotriazole in mixtures of dichloromethane and N,N-dimethylformamide. N alpha-deprotection is accomplished with trifluoroacetic acid. Finally, hydrogenation with palladium on charcoal and ammonium formate produces the pure hexapeptide. A new one-pot synthesis of Boc-Arg(Z2) is described, and the use of this derivative in peptide coupling is studied. The synthetic peptide was coupled to BSA and used in direct immunication of rabbits.

Synthesis of a putative antigenic heptapeptide from Escherichia coli K88 ab protein fimbriae.

The heptapeptide Tyr-Arg-Glu-Asp-Met-Glu-Tyr-OMe, spanning region 213-219 of Escherichia coli K88 ab protein fimbriae, was synthesized with an overall yield of 37% using dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBt) preactivation in all condensation reactions. The C-terminal was protected as the methyl ester. The protection scheme of N alpha-tert-butyloxycarbonyl-(Boc) and benzyl-(Bzl) or benzyloxycarbonyl (Z) groups for side chain protection was found to be orthogonal when a mixture of trifluoroacetic acid (TFA), phenol (PhOH) and p-cresol (CrOH) was used for repetitive deprotection. The final deprotection of Boc-Tyr(Bzl)-Arg(Z2)-Glu(Bzl)-Asp(Bzl)-Met-Glu(Bzl+ ++)-Tyr(Bzl)-OMe (17) was accomplished in 80% yield by prolonged treatment with hydrogen fluoride, dimethyl sulfide, p-cresol and p-thiocresol. The BSA-linked synthetic peptide was used in immunisation experiments on rabbits.